Table 2 CM-based DDS for the treatment of IBD
From: Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
Carrier | Experiment model | Encapsulated cargoes | Status | Therapeutic application and observations | References |
|---|---|---|---|---|---|
NPs derived from ginger | DSS-induced colitis mouse model | – | In vitro and in vivo | Oral administration of GDNPs increased the survival and proliferation of IECs, reduced pro-inflammatory cytokines, and increased the anti-inflammatory cytokines in colitis models | [119] |
NPs derived from ginger | Colon-26 and RAW 264.7 cells, normal mice | siCD98 | In vitro and in vivo | Ginger-derived lipid vesicles can encapsulate siCD98 and a very low dose of siCD98 after oral administration specifically and efficiently reduced colonic CD98 gene expression | [120] |
Angelica polysaccharide | TNBS-induced UC in rats | Dexamethasone (Dex) | In vivo | The Angelica polysaccharide-Dex conjugate greatly reduced the systemic immunosuppression caused by Dex and effectively conveyed Dex to the large intestine | [126] |
Inulin | DSS-induced colitis mouse model | Budesonide | In vivo | The redox-sensitive NPs, based on amphiphilic inulin, specifically delivered budesonide to the inflamed colon tissue and exerted excellent therapeutic efficacy in comparison to drug suspension in colitis mice model | [131] |
In situ self-spray coating system (DTPA dianhydride, SBC, SDS) | Caco-2 cells, raw 264.7 macrophage, DSS-induced rat colitis | Diallyl trisulfide (DATS) | In vitro and in vivo | Rectal administration of the DATS-loaded self-spray system produced exogenous H2S and suppressed the overproduction of pro-inflammatory cytokines, inhibited the adhesion of macrophages on the vascular endothelium, and repaired colonic inflamed tissues | [136] |